Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05190159 · ClinicalTrials.gov registry record
Monster Screw System Post-Market Clinical Follow-Up Study
A clinical trial, sponsored by Paragon 28.
- Completed
- Registry status
- 82
- Enrollment target
NCT05190159: Completed study, sponsored by Paragon 28.
NCT05190159 is a clinical trial that has completed, run by Paragon 28. The registered enrollment target is 82 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05190159 has completed, sponsored by Paragon 28.
- COMPLETED
- Registry status
- 82 participants
- Enrollment target
Study Summary
Post-market clinical follow-up study on the Monster Screw System
Primary Outcome
Safety will be assessed by recording the incidence of secondary procedures related to the index procedure
Interventions
- DEVICE Monster Screw System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 82 participants |
| Start Date | 2022-01-26 |
| Est. Completion | 2022-09-21 |
What the finished NCT05190159 record still lists
NCT05190159 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 82 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Monster Screw System is the first listed.
NCT05190159 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05190159 about?
NCT05190159 is a clinical study titled "Monster Screw System Post-Market Clinical Follow-Up Study". Post-market clinical follow-up study on the Monster Screw System
What is the current status of trial NCT05190159?
This trial is currently completed. The enrollment target is 82 participants. The study started on 2022-01-26. Estimated completion is 2022-09-21.
What interventions are being tested in trial NCT05190159?
The interventions under investigation include: Monster Screw System (DEVICE).
Who is sponsoring clinical trial NCT05190159?
This trial is sponsored by Paragon 28, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03319901 · 82 participants · Phase 1
Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL
- NCT03493425 · 82 participants · Phase 2
Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery
- NCT04105270 · 82 participants · Phase 2
RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial
- NCT04428658 · 82 participants · NA
Randomized Trial of Supplemental Synchronous and Asynchronous Telehealth to Improve Glycemic Control for Pediatric Patients With Type 1 Diabetes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI